Broadening participation in clinical trials: A win for all

The objective is to engage in rea l-world, evidence-based research and bring trials to the local community, where a significant proportion of cancer care is rendered,” he adds.   To help, Cardinal Health ’s real-world evidence and insights teams analyze the real-world data collected from the sites, which can be compared to results from clinical trials to demonstrate the real-world value of therapies.   By bringing these studies to the community, many of the usual challenges are overcome, adds Gajra. These include trial site location (typically academic institutions) and the distances that must be traveled to reach a trial site on multiple occasions, which make it expensive and time-consuming for some populations to participate, especially if they cannot take time off from work.   Incorporating the virtual The Cardinal Health executives believe that using community-based principal investigators and trial sites offsets some of these issues and makes strides toward diversity in clinical trials. “Choosing a principal investigator from the community who has access to a large number of patients is essential in getting more diverse populations to participate,” says Gajra.  The events of 2020 have served to further improve trials and broaden participation at the same time. “COVID-19 has opened our eyes to some inefficiencies in how we conduct clinical trials,” says Zettler. “Incorporating virtual elements into trials when possible is one way to make trials le...
Source: EyeForPharma - Category: Pharmaceuticals Authors: Source Type: news